Heidi S. Camp

机构：AbbVie (United States) · ORCID：0009-0003-2632-015X

发表论文 102 篇 · 总被引 6300 次 · h-index 32

代表论文

• Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study (2024 · EClinicalMedicine · 被引 58)
• Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study (2025 · Journal of the American Academy of Dermatology · 被引 28)
• Comorbidity Burden Among Patients with Vitiligo in the United States: A Large-Scale Retrospective Claims Database Analysis (2023 · Dermatology and Therapy · 被引 27)
• Economic Burden among Patients with Vitiligo in the United States: A Retrospective Database Claims Study (2023 · Journal of Investigative Dermatology · 被引 19)
• Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial (2024 · Arthritis Research & Therapy · 被引 16)
• Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location (2024 · Dermatology and Therapy · 被引 16)